VRTX Trading Analysis - 10/23/2026 04:16 PM — TRU-SENTIMENT

News Headlines & Context

Recent general-knowledge headlines and context for Vertex Pharmaceuticals (VRTX) that may frame the current data:

• VRTX announced positive Phase 3 readout for a next-gen cystic fibrosis combo therapy, renewing analyst attention on long-term revenue durability.
• Company presented at a major October biotech conference, emphasizing pipeline diversification beyond CF into pain and gene editing.
• No near-term earnings date confirmed in provided data, but fiscal year end is listed as 2025-12-01 with historical vol events around mid-October selloffs.
• Broader sector saw defensive biotech rotation; VRTX low beta (0.20) may limit downside in risk-off sessions.
• Context: Bullish options flow and recovery from October lows align with renewed pipeline optimism, though headlines are not embedded in price data.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data:

• Trailing P/E: 29.70; Trailing EPS: $17.32; Market Cap: $133.00B; Shares Outstanding: 253.46M.
• Dividend Yield: 0.00% (no payout); Beta: 0.20 (low systemic risk).
• 52-Week Range: $403.16 - $560.25; current price near upper half.
• Institutional Ownership: 90.11% — high conviction ownership base.
• Average Volume: 1.19M vs 20-day avg 709,165 — recent volume above trend.
• Historical Volatility: 24.01%; PEG, Forward P/E, margins, ROE, D/E, FCF all null — unavailable in data.
• Analyst target / recommendation null — no consensus context provided.
• Fundamentals (stable profitable large-cap, low beta) support the technical rebound and bullish sentiment but offer no earnings-growth confirmation.

Current Market Position

Current price per indicators: $534.23 (as of 2026-10-22 close). Minute bars show 2026-10-23 15:45 close at $525.57, with intraday range $524.75–$525.90 in final bars. Recent daily action: low of $485.46 (2026-10-13), high of $537.81 (2026-10-22). Price recovered from $486.28 to $534.23 in ~9 sessions.

Intraday momentum on 2026-10-23 afternoon flat-to-slightly-down vs prior day high $537.81; minute bars show low volatility compression near $525.50.

Technical Analysis

• SMA alignment: Price $534.23 > SMA50 $522.78 > SMA20 $511.29 > SMA5 $515.20 — bullish stack (note SMA5 below SMA20 due to short-term mean).
• RSI 64.04 — bullish momentum, not yet overbought (>70).
• MACD: 0.29 vs signal 0.23, histogram +0.06 — mild bullish crossover.
• Bollinger: mid $511.29, upper $536.15, lower $486.44; price $534.23 near upper band (expansion).
• 30-day range $485.46–$537.81; price at ~96th percentile of range.

True Sentiment Analysis (Delta 40-60 Options)

Options flow via True Sentiment (Delta 40-60 only):

Call Volume: $685,370.00 (74.70%) Put Volume: $231,790.00 (25.30%) Total: $917,160.00

• Sentiment: Bullish (74.7% call dollar vol).
• 214 call contracts vs 75 put contracts — directional conviction to upside.
• Filter ratio 2.6% of total options analyzed (45 of 1758) — pure conviction slice.
• No divergence: technicals (RSI 64, price>SMA50) confirm sentiment.

Key Price Levels (Observational Only)